诺唯赞参与学术会议并达成战略合作，推动阿尔茨海默病早期诊断

Group 1 - Core viewpoint: NuoVance is actively participating in Alzheimer's disease research and has established strategic partnerships to enhance early diagnosis and treatment [1][2] - NuoVance participated in an academic conference on plasma biomarkers for Alzheimer's disease, contributing to multi-center research in the Northwest [1] - The company has formed a strategic cooperation with Taikang Medical to develop a new ecosystem for Alzheimer's prevention and treatment, focusing on the application of blood biomarkers in grassroots settings [1] Group 2 - As of February 12, 2026, NuoVance's stock price was 20.90 yuan, reflecting a decrease of 0.76% on that day, with a trading volume of 15.72 million yuan [2] - Over the past five days, the stock has seen a cumulative decline of 0.43%, with a narrowing fluctuation range of 1.09% [2] - Recent capital flow indicates a net inflow of 71,100 yuan from institutional investors on February 11 and a net inflow of 810,500 yuan on February 12, while retail investors showed a net outflow [2]